Lidokain Viatris (Lidocaine Hydrochloride)

Lidocaine works by reversibly blocking voltage‑gated sodium channels on neuronal membranes. This blockade prevents the rapid influx of sodium ions needed for depolarisation, thereby inhibiting the initiation and propagation of nerve impulses and reducing pain signals and abnormal cardiac conduction.

The specific dose of Lidokain Viatris is determined by the prescribing clinician based on the indication, patient weight, age, and clinical condition. Healthcare professionals calculate the appropriate amount to achieve effective anesthesia while minimizing the risk of toxicity.

Safety data for lidocaine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration, making it suitable for short procedures and cardiac applications. Compared with ester‑type agents such as procaine, lidocaine has a lower risk of allergic reactions and a more predictable pharmacokinetic profile.

Lidokain Viatris should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. If the solution reaches room temperature, it may be used for a limited period as indicated by the manufacturer’s label.

The product is supplied as a sterile injectable solution intended for intravenous administration. It is typically drawn into a syringe and injected slowly under aseptic conditions, with dosing and infusion rate determined by the treating physician.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias such as ventricular tachycardia, central nervous system toxicity leading to seizures, and methemoglobinemia. Prompt recognition and management of these events are essential.

Patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe hepatic impairment, and individuals with certain cardiac conduction disorders should avoid using Lidokain Viatris unless a specialist determines that benefits outweigh the risks.